New drug cocktail targets tough lung cancers in major trial
NCT ID NCT07309276
Summary
This study is testing whether combining a new drug called JS212 with other cancer medications can help control advanced lung cancer. Researchers will enroll about 864 patients whose cancer has progressed despite standard treatments or who haven't yet received systemic therapy. The main goal is to see how many patients' tumors shrink significantly and to monitor side effects of these drug combinations.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital
Shanghai, Shanghai Municipality, 200120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.